Vital Biosciences Unveils Revolutionary POC Lab Testing Platform

Vital Biosciences (Toronto, ON, Canada) is making waves at AACC 2023 with the introduction of its game-changing product, the VitalOne. This groundbreaking innovation with the potential to completely redefine diagnostics was unveiled to thousands of laboratory experts at the AACC annual gathering. Furthermore, VitalOne was recognized as the Audience Choice winner at this year's AACC Disruptive Technology Award.

For years, routine lab testing has been a cornerstone of clinical guidelines. Currently, medical decisions rely on laboratory test results 70% of the time. However, it's concerning that nearly 30% of electronic lab orders remain unfulfilled. For instance, about 20% of American adults with diabetes remain undiagnosed, and a staggering 80% of prediabetic individuals are oblivious to their condition. Preventing chronic diseases such as hyperlipidemia, type 2 diabetes, or congestive heart failure is best achieved through early detection and intervention. Unfortunately, the existing testing, diagnosis, and treatment process is not universally accessible.

The VitalOne aims to democratize blood diagnostics by making over 50 lab-grade tests — covering 95% of routine lab orders — available at primary care locations, all packaged within a device no bigger than a desktop computer. With VitalOne, physicians can conduct tests, diagnose, and treat patients all in one appointment, with results obtained in 20 minutes. The underlying technology has been rigorously tested and validated against thousands of samples in comparison to gold-standard instruments, through collaborations with Vital's lab partners.

Vital is redefining point-of-care testing with the development of the VitalOne, envisaging a future where patients do not need to sacrifice work hours, commute between their primary care doctor and a lab, or endure days of waiting to discuss their results. Bridging this gap will make diagnostics more accessible and speed up clinical interventions, helping prevent adverse outcomes and disease progression. VitalOne is currently in its late-stage product development and is yet to be made commercially available. Additional clinical studies are scheduled for later this year. Moreover, Vital is keen on forming partnerships with industry, academia, and the laboratory medicine community for further performance evaluations and feedback.

“We started Vital to make high-quality care more accessible to millions of people and realized how limited we were by our current diagnostic infrastructure,” said Vasu Nadella, CEO and Co-Founder of Vital Biosciences. “We seek to disrupt the USD 85 billion diagnostics industry by bringing lab-grade diagnostics everywhere and eliminating the impediments to proactive and accessible care.”

“We live in a world where you can order a pizza and have it delivered in 20 minutes but your lab results take days. That’s not okay,” added Mounir Koussa, Co-Founder and VP of Research and Development at Vital. “We want to ensure that diagnostics are available wherever and whenever they are needed, and that testing never becomes an impediment to treatment and care.”

Related Links:
Vital Biosciences